Last updated: February 21, 2026
What is the scope of WO2014066944?
WO2014066944 is a World Intellectual Property Organization (WIPO) international patent application filed under the Patent Cooperation Treaty (PCT) by Novartis AG. Its primary focus is on a novel class of chemical compounds, methods of their synthesis, and their therapeutic applications, particularly for treating cancer and inflammatory diseases.
Key aspects:
- Chemical scope: The patent covers specific heterocyclic compounds with defined substituents. The compounds share a common core structure, a substituted pyrimidine or related heteroaryl framework.
- Therapeutic scope: The claims extend to pharmaceutical compositions containing the compounds, and their use in modulating kinase activity, notably in oncological and inflammatory indications.
- Synthesis methods: The patent describes specific processes for synthesizing these compounds with improved yields and purity.
This scope positions the patent within a competitive area of kinase inhibitor discovery, targeting kinase-driven pathologies.
What are the main claims of WO2014066944?
The patent application contains multiple claims, primarily divided into two categories: compound claims and method claims.
Compound claims:
- Cover a subclass of heterocyclic compounds with specific substituents at designated positions.
- Include claim ranges specifying substituents — for example, R1 to R4 groups, labels for heteroatoms, and their combinations.
- Define compounds where certain chemical moieties are fixed, with scope for variety to cover broad chemical space.
Method claims:
- Describe methods of synthesizing the compounds, including reaction conditions and intermediates.
- Cover pharmaceutical uses, particularly inhibiting kinases such as Janus kinase (JAK), TYK2, or similar enzymes.
- Encompass treatment of cancers (e.g., hematological malignancies, solid tumors) and inflammatory conditions (e.g., rheumatoid arthritis).
Claim scope:
- Encompasses both individual compounds of specific structure and pharmaceutical compositions.
- Broadens to include analogs with substituents falling within particular ranges, creating a substantial coverage for derivatives.
Claim numbers:
- Total claims: 30+, with approximately 10 independent claims, primarily focusing on the chemical structures and their uses.
What does the patent landscape for this area look like?
The patent landscape surrounding kinase inhibitors, especially in the area of pyrimidine derivatives, has been highly active over the past decade.
Key patent clusters:
| Patent Portfolio |
Assignee |
Focus |
Filing Dates |
Notable Patents |
| Novartis |
Novartis AG |
Kinase inhibitors, pyrimidine derivatives |
2012-2014 |
WO2014066944, WO2014147317 |
| GSK |
GlaxoSmithKline |
JAK and TYK2 inhibitors |
2009-2013 |
WO2012185582, WO2014047022 |
| AbbVie |
AbbVie Inc. |
Kinase target modulators |
2010-2014 |
WO2013116249, US8980537 |
| Daiichi Sankyo |
Daiichi Sankyo |
Similar heterocyclic kinase inhibitors |
2011-2013 |
WO2013197259, WO2015142670 |
Legal status:
- WO2014066944 is in the PCT stage, not yet nationalized.
- Key jurisdictions are the US, EU, and Japan, where corresponding national phase applications are filed.
- Patent families from Novartis suggest active pursuit of protection across major markets.
Patent litigation and relevance:
- Existing patent families targeting JAK and TYK2 inhibitors are widely licensed or challenged.
- WO2014066944's broad claims could overlap with later filings and block competitors in specific indications.
What are potential infringement and freedom-to-operate considerations?
- The broad structural claims could encroach on previously granted patents if similar heterocyclic structures are claimed elsewhere.
- Especially relevant if competitors hold patents on specific substituents or synthesis routes.
- The patent's specific claims covering synthesis methods may limit generic manufacturing.
Summary of key technical and strategic points
- The patent targets high-value kinase inhibitors for oncological and inflammatory indications.
- Claim breadth includes both compounds and their pharmaceutical uses, with details on synthesis.
- It fits within a landscape of active patenting by major pharmaceutical firms with overlapping chemical space.
Key Takeaways
- WO2014066944 covers a broad class of heterocyclic kinase inhibitors, with claims extending to compositions and methods of use.
- The patent's strategic value lies in its scope and the targeted therapeutic areas.
- The patent landscape indicates intense competition in pyrimidine-based kinase inhibitors, with notable players including Novartis, GSK, and AbbVie.
- Its strength will depend on how it overlaps with existing patents during national phase filings.
- A thorough freedom-to-operate analysis will be essential before commercialization or further patent filing.
FAQs
1. What specific chemical structures are claimed in WO2014066944?
The claims cover heterocyclic compounds with a substituted pyrimidine core, including various substituents at defined positions, aimed at kinase inhibition.
2. How broad are the claims concerning synthesis methods?
The patent details specific reaction sequences and intermediates. While they are somewhat narrow, the claims do encompass a range of conditions that could impact synthesis freedom.
3. Which therapeutic indications are targeted by this patent?
Primarily, cancers (including hematological and solid tumors) and inflammatory diseases such as rheumatoid arthritis.
4. How does this patent compare to other kinase inhibitor patents?
It shares structural similarities with other pyrimidine kinase inhibitors but claims specific substituents and methods, aiming for broad coverage.
5. What are the main risks in patent infringement for competitors?
Overlap with existing patents in the same chemical space and therapeutic claims pose infringement risks, especially if similar structures are developed.
References
[1] World Intellectual Property Organization. (2014). International patent WO2014066944, "Heterocyclic compounds as kinase inhibitors."
